| US 7,569,554 B2 | ||
| Synergistic treatment of cancer using immunomers in conjunction with therapeutic agents | ||
| Ekambar R. Kandimalla, Southboro, Mass. (US); Sudhir Agrawal, Shrewsbury, Mass. (US); Daqing Wang, Bedford, Mass. (US); Lakshmi Bhagat, Framingham, Mass. (US); and Dong Yu, Westboro, Mass. (US) | ||
| Assigned to Idera Pharmaceuticals, Inc., Cambridge, Mass. (US) | ||
| Filed on May 14, 2004, as Appl. No. 10/846,167. | ||
| Claims priority of provisional application 60/471247, filed on May 16, 2003. | ||
| Prior Publication US 2005/0009773 A1, Jan. 13, 2005 | ||
| This patent is subject to a terminal disclaimer. | ||
| Int. Cl. A61K 39/395 (2006.01); A61K 31/7105 (2006.01); A61K 31/7115 (2006.01); A61K 31/7125 (2006.01) | ||
| U.S. Cl. 514—44 [424/130.1; 424/156.1] | 2 Claims |
1. A method for treating cancer comprising administering to a patient an immunomer in combination with a monoclonal antibody
selected from Panorex® (edrecolomab), Rituxan® (rituximab), Mylotarg® (gemtuzumab ozogamicin), Campath® (alemtuzumab), Zevalin®
(ibritumomab tiuxetan), Bexxar® (tositumomab), Erbitux® (cetuximab), Avastin® (bevacizumab or Herceptin® (trastuzumab), wherein
the immunomer comprises the structure 5′-TCGTTGX-Y-XGTTGCT-5′ wherein X is a C3 linker and Y is a glycerol linker or comprises
the structure (SEQ ID NO 18):
| |||||||||
| and wherein the anti-tumor effects of the monoclonal antibody are enhanced when administered in combination with the immunomer. |